Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
172 results about "Sodium channel blocker" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Sodium channel blockers are drugs which impair the conduction of sodium ions (Na⁺) through sodium channels.
Phenyl guanidine sodium channel blockers
InactiveUS6858615B2Increased mucociliary clearanceAbsorbed less rapidlyBiocideSenses disorderStructural variableGuanidine
The present invention relates to a compound represented by formula (I): in which at least one of R3 and R4 is a group represented by formula (A): where the structural variables are as defined herein. The compounds are useful for blocking sodium channels.
Owner:PARION SCI DURHAM NC
Phenolic guanidine sodium channel blockers
InactiveUS6858614B2Increased mucociliary clearanceAbsorbed less rapidlyBiocideSenses disorderGuanidineSodium channel blocker
The present invention relates to compounds represented by formula (I): in which at least one of R3 and R4 is a group represented by formula (A): where the structural variables are defined herein. The compounds are useful for blocking sodium channels.
Owner:PARION SCI DURHAM NC
Sodium channel blockers
InactiveUS6903105B2More potent and/or absorbed less rapidlyLess reversibleOrganic active ingredientsSenses disorderTreatment useCalcium channel blocker
The present invention relates to pyrazinoylguanidine compounds represented by formula (I): where at least one of R3 and R4 is a group represented by formula (A): where the other structural groups are defined herein. The present invention also includes a variety of methods of treatment using these sodium channel blockers.
Owner:PARION SCI DURHAM NC
Sodium channel blockers
InactiveUS7192958B2More potent and/or absorbed less rapidlyLess reversibleBiocideSenses disorderChannel blockerCalcium channel blocker
The present invention relates to compounds represented by formula (I):in which at least one of R3 and R4 is a group represented by formula (A):where the structural variables are defined herein. The compounds are useful for blocking sodium channels.
Owner:PARION SCI DURHAM NC
Sodium channel blockers
InactiveUS7186833B2More potent and/or absorbed less rapidlyLess reversibleOrganic active ingredientsSenses disorderOrganic chemistryMedicinal chemistry
Owner:PARION SCI DURHAM NC
Sodium channel blockers
InactiveUS7192959B2More potent and/or absorbed less rapidlyLess reversibleBiocideSenses disorderStructural variableStereochemistry
The present invention relates to compounds represented by formula (I):in which at least one of R3 and R4 is a group represented by formula (A):where the structural variables are defined herein. The compounds are useful for blocking sodium channels.
Owner:PARION SCI DURHAM NC
Cyclic pyrazinoylguanidine sodium channel blockers
ActiveUS7317013B2More potent and/or absorbed less rapidlyLess reversibleOrganic active ingredientsSenses disorderChannel blockerStructural variable
Owner:PARION SCI DURHAM NC
Directed delivery of agents to neural anatomy
InactiveUS20120310140A1Effective pain managementAdequate pain reliefSpinal electrodesPharmaceutical delivery mechanismDiseaseAutomatic control
The present invention is directed generally to systems, devices and methods for direct delivery of agents, e.g., pharmaceutical agents, to target spinal and neuronal anatomies, e.g., the dorsal root ganglia (DRG), for the treatment of various disorders, particularly pain and pain related disorders, such as chronic itch, sensory disorders, multiple sclerosis, post-herpetic neuralgia and the like. The system, devices and methods of the invention encompass the agents to be delivered to the target anatomy alone or in combination with electrical stimulation. The delivery device and systems and methods as disclosed herein place the distal end of the delivery element, which comprises at least one agent delivery structure, and optionally at least one electrode, in close proximity, or in contact with or next to the target spinal anatomy, e.g., DRG. A variety of agents can be delivered using the device, including sodium channel blockers, biologics, neuroinflammatory modulators, toxins etc., to selectively neuromodulate the neurons. Agent delivery and / or electrical stimulation can be automated and / or can be controlled automatically or by a pre-determined program, or by a patient control pump (PCA).
Owner:ST JUDE MEDICAL LUXEMBOURG HLDG SMI S A R L SJM LUX SMI
Alaphatic pyrazinoylguanidine sodium channel blockers
ActiveUS7375107B2More potent and/or absorbed less rapidlyLess reversibleBiocideOrganic active ingredientsDiseasePyrazine
Owner:PARION SCI DURHAM NC
Methods of reducing risk of infection from pathogens
InactiveUS20050080093A1Reduce the risk of infectionAntibacterial agentsBiocideNatural sourceMedicine
Prophylactic treatment methods are provided for protection of individuals and / or populations against infection from airborne pathogens. In particular, prophylactic treatment methods are provided comprising administering a sodium channel blocker or pharmaceutically acceptable salts thereof to one or more members of a population at risk of exposure to or already exposed to one or more airborne pathogens, either from natural sources or from intentional release of pathogens into the environment.
Owner:PARION SCI DURHAM NC
Capped pyrazinoylguanidine sodium channel blockers
InactiveUS7807834B2Prolonged pharmacodynamic half-lifeMore potent and/or absorbed less rapidlySenses disorderNervous disorderChannel blockerCalcium channel blocker
The present invention relates to group of pyrazinoylguanidine compounds useful as sodium channel blockers. The compounds may be used to promote promoting hydration of mucosal surfaces.
Owner:PARION SCI DURHAM NC
Methods of enhancing mucosal hydration and mucosal clearance by treatment with sodium channel blockers and osmolytes
ActiveUS20080090841A1More specificLess reversibleAntibacterial agentsOrganic active ingredientsOtic AgentsOsmolyte
The present invention relates to methods and compositions for treating diseases ameliorated by increased mucociliary clearance and mucosal hydration by administering an effective amount of a sodium channel blocker as defined herein and an osmolyte to a subject to a subject in need of increased mucociliary clearance and mucosal hydration.
Owner:PARION SCI DURHAM NC
Sodium channel blockers
InactiveUS20060142306A1More potent and/or absorbed less rapidlyLess reversibleOrganic active ingredientsSenses disorderTreatment useChemistry
Owner:CYFI
Alaphatic pyrazinoylguanidine sodium channel blockers
ActiveUS20050080092A1Absorbed less rapidlyMore potentOrganic active ingredientsSenses disorderChannel blockerTreatment use
Owner:PARION SCI DURHAM NC
Compositions and methods for enhancing cognitive function and synaptic plasticity
InactiveUS20060089335A1Improve cognitive functionEnhance synaptic plasticityBiocidePeptide/protein ingredientsNR1 NMDA receptorAction potential firing
The present invention provides compositions and methods for enhancing cognitive function and synaptic plasticity. According to the method, Ca++ influx into excitatory neurons (nerve cells) is decreased by treatment with a number of different agents including divalent cations (e.g., Mg++), GABAB agonists, GABAA agonists, calcium channel blockers, and / or compounds that decrease action potential firing such as sodium channel blockers. Decreasing Ca++ influx results in increased synaptic plasticity and enhanced cognitive function. In particular, decreasing Ca++ influx associated with uncorrelated neural activity results in long-lasting increases in synaptic plasticity and cognitive function. This is achieved by administration of agents that cause a voltage-dependent block of NMDA receptors (e.g., divalent cations such as Mg++) or by administration of GABAB agonists such as baclofen. The invention further provides screening methods useful in identifying compounds that enhance synaptic plasticity and cognitive function.
Owner:MASSACHUSETTS INST OF TECH
Aliphatic amide and ester pyrazinoylguanidine sodium channel blockers
InactiveUS7956059B2More potent and/or absorbed less rapidlyLess reversibleOrganic active ingredientsSenses disorderCombinatorial chemistryChannel blocker
The present invention relates to pyrazinoylguanidine compounds represented by formula (I):where the structural variables are defined herein. The compounds are useful as, for example, sodium channel blockers.
Owner:PARION SCI DURHAM NC
Poly aromatic pyrazinoylguanidine sodium channel blockers
ActiveUS8124607B2More potent and/or absorbed less rapidlyLess reversibleOrganic active ingredientsSenses disorderChannel blockerTreatment use
Owner:PARION SCI DURHAM NC
Soluble amide & ester pyrazinoylguanidine sodium channel blockers
ActiveUS20060040954A1More potent and/or absorbed less rapidlyLess reversibleBiocideOrganic active ingredientsChannel blockerTreatment use
Owner:PARION SCI DURHAM NC
Cyclic amide and ester pyrazinoylguanidine sodium channel blockers
ActiveUS8143256B2More potent and/or absorbed less rapidlyLess reversibleOrganic active ingredientsSenses disorderCombinatorial chemistryChannel blocker
The present invention provides compounds represented by formula (I):where the structural variables are defined herein. The compound of the present invention are useful as sodium channel blockers.
Owner:PARION SCI DURHAM NC
Methods of enhancing mucosal hydration and mucosal clearance by treatment with sodium channel blockers and osmolytes
InactiveUS8058278B2More specificAbsorbed less rapidlyAntibacterial agentsOrganic active ingredientsDiseaseOsmolyte
Owner:PARION SCI DURHAM NC
Phenyl substituted pyrazinoylguanidine sodium channel blockers possessing beta agonist activity
ActiveUS8163758B2More potent and/or absorbed less rapidlyLess reversibleOrganic active ingredientsSenses disorderDiseaseAgonist
Owner:PARION SCI DURHAM NC
Methods of enhancing mucosal hydration and mucosal clearance by treatment with sodium channel blockers and osmolytes
The present invention relates to methods and compositions for treating diseases ameliorated by increased mucociliary clearance and mucosal hydration by administering an effective amount of a sodium channel blocker as defined herein and an osmolyte to a subject to a subject in need of increased mucociliary clearance and mucosal hydration.
Owner:PARION SCI DURHAM NC
Methods of reducing risk of infection from pathogens
Prophylactic treatment methods are provided for protection of individuals and / or populations against infection from airborne pathogens. In particular, prophylactic treatment methods are provided including administering a sodium channel blocker or pharmaceutically acceptable salts thereof to one or more members of a population at risk of exposure to or already exposed to one or more airborne pathogens, either from natural sources or from intentional release of pathogens into the environment.
Owner:PARION SCI DURHAM NC
Substituted piperidines as sodium channel blockers
The present disclosure provides substituted piperidines or pyrrolidines having Formula IA:and the pharmaceutically acceptable salts and solvates thereof, wherein R1, R2a, R2b, R6, A, X, m and n are defined as set forth in the specification. In certain embodiments, Compounds of the present disclosure are useful for treating pain. The present disclosure is also directed to the use of Compounds of the present disclosure to treat a disorder responsive to blockade of one or more sodium channels.
Owner:PURDUE PHARMA LP
Prolonged suppression of electrical activity in excitable tissues
InactiveUS20050202093A1Reduce particle agglomerationPromote absorptionPowder deliveryGranular deliveryControlled releaseDisease
Controlled release of pharmaceutical agents using microspheres or other controlled release systems are used to treat disease state characterized by aberrant electrical activity in excitable tissue. For the treatment of epilepsy, agents useful in the treatment of epilepsy may be delivered to the patient at the site of seizure origin to control seizure activity in a time release manner. The inventive system may also be useful in the treatment of cardiac arrhythmias and pre-term labor. Particularly useful pharmaceutical compositions comprising a site 1 sodium channel blocker are also provided.
Owner:MASSACHUSETTS INST OF TECH +1
Aliphatic pyrazinoylguanidine sodium channel blockers with beta agonist activity
ActiveUS8324218B2More potent and/or absorbed less rapidlyLess reversibleOrganic active ingredientsSenses disorderDiseaseSinusitis
The present application provides sodium channel blockers exemplified by the following structure:The compounds of the invention useful for treating chronic bronchitis, cystic fibrosis, sinusitis, vaginal dryness, dry eye, Sjogren's disease, distal intestinal obstruction syndrome, dry skin, esophagitis, dry mouth (xerostomia), nasal dehydration, ventilator-induced pneumonia, asthma, primary ciliary dyskinesia, otitis media, chronic obstructive pulmonary disease, emphysema, pneumonia, constipation, and chronic diverticulitis, for example.
Owner:PARION SCI DURHAM NC
Cyclic pyrazinoylguanidine sodium channel blockers
ActiveUS20050059676A1More potentLess reversibleOrganic active ingredientsSenses disorderChannel blockerTreatment use
Owner:PARION SCI DURHAM NC
Substituted Pyridines as Sodium Channel Blockers
The invention relates to substituted pyridine compounds of Formula I: (I) and the pharmaceutically acceptable salts, prodrugs, and solvates thereof, wherein R1a, R1b, R2a, R2b, R2c, A1, A2, and X are defined as set forth in the specification. The invention is also directed to the use of compounds of Formula I to treat a disorder responsive to the blockade of sodium channels. Compounds of the present invention are especially useful for treating pain.
Owner:PURDUE PHARMA LP
Sodium channel blocker compositions and the use thereof
Methods of treating or preventing chronic pain or convulsion are disclosed by administering to an animal a sodium channel blocker and at least one of gabapentin and pregabalin. Also disclosed are pharmaceutical compositions and kits for the treatment or prevention of chronic pain or convulsion.
Owner:EURO-CELTIQUE SA
Cyclic Amide & Ester Pyrazinoylganidine Sodium Channel Blockers
ActiveUS20080096896A1More potentLess reversibleOrganic active ingredientsSenses disorderChannel blockerTreatment use
Owner:PARION SCI DURHAM NC
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com